Development of a Novel Oral Anticoagulant with Minimal Bleeding Risk

点击翻译按钮获取中文摘要

The generation of a blood clot in a vein or artery is a very serious condition, ultimately causing 225,000 deaths per year in the UK alone. Anticoagulants are prescribed to prevent or treat blood clots. Patients that have an abnormal heart rhythm [atrial fibrillation (AF)] are 5 times more likely to have a blood clot in the brain (stroke). Warfarin, an anticoagulant drug, can reduce this high risk of stroke by 64%. However, warfarin is a difficult drug to administer as it needs to be monitored with a blood sample every month to ensure the correct level of drug is in the body. Furthermore, warfarin carries a risk of causing major bleeding for up to 3 in 100 patients taking the drug of which 1 in 8 will die. Recently a new drug, dabigatran has been approved for long term use to treat patients with AF. The benefit of this new drug is that patients no longer need to be monitored with a blood sample. However, one problem that all existing anticoagulant drugs and the new ones that are being developed have is that they still carry a very high risk of bleeding. In this proposal, we are developing for the first time a new anticoagulant drug that will not need monitoring and is not likely to result in bleeding when used. If we are successful, this has the potential to transform anticoagulation treatment, improve patient quality of life and make large savings to the cost of patient healthcare through not having to treat bleeding complications.